5-ethyl-heptan-3-one | 6137-18-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-ethyl-heptan-3-one
• 英文别名: 5-Aethyl-heptan-3-on；5-Ethylheptan-3-one
• CAS: 6137-18-4
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: DMRZSXNCIFGKME-UHFFFAOYSA-N

物化性质

• 沸点：
  179-181 °C
• 密度：
  0.8341 g/cm3(Temp: 15 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5-ethyl-1-methoxy-hept-4-en-3-one 在 对甲苯磺酸 、 铂 作用下， 生成 5-ethyl-heptan-3-one
  参考文献：
  名称：

  Nasarow, Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1940, p. 556

  摘要：

  DOI：

文献信息

• [EN] PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DERIVES DE PYRIDAZINONE, PROCEDES DE PRODUCTION DE CES DERIVES ET LEUR UTILISATION COMME PHARMACEUTIQUES
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2005111018A1

  公开（公告）日：2005-11-24

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. Formula (I) These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK­15 30 (glycogen synthase kinase-3ß).

  本发明涉及通式（I）所示的化合物，其中下文给出了取代基X、R1和R2的定义，以及它们的生理上可接受的盐，生产这些化合物的方法以及它们作为药物的用途。通式（I）这些化合物是激酶抑制剂，特别是激酶GSK-15 30（糖原合成酶激酶-3ß）的抑制剂。
• [EN] PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS<br/>[FR] DERIVES DE PYRIDAZINONES EN TANT QU'INHIBITEURS DE GSK-3BETA
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2004046117A1

  公开（公告）日：2004-06-03

  The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl (C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-­alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10 alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.

  本发明涉及通式（I）中的新型吡啶酮衍生物，其中A是A1或A2；R是未取代或至少单取代的C1-C10-烷基、芳基、芳基（C1-C10-烷基）、杂芳基、杂芳基（C1-C10-烷基）、杂环基、杂环基（C1-C10-烷基）、C3-C10环烷基、多环烷基、C2-C10烯基或C2-C10炔基，Ar是未取代或至少单取代的芳基或杂芳基。
• Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20030212070A1

  公开（公告）日：2003-11-13

  The present invention relates to aminoalkyl-substituted aromatic bicyclic compounds of formula I, 1 which are valuable pharmaceutically active compounds that are suitable, for example, for the treatment of obesity, type II diabetes, arteriosclerosis, high blood pressure, paresthesia, depression, anxiety, anxiety neuroses, schizophrenia, disorders associated with the circadian rhythm, and drug abuse, as well as normalizing lipid metabolism.

  本发明涉及公式I的氨基烷基取代芳香双环化合物，这些化合物是有价值的药用活性化合物，例如适用于治疗肥胖症、2型糖尿病、动脉硬化、高血压、感觉异常、抑郁症、焦虑症、焦虑神经症、精神分裂症、与昼夜节律相关的疾病以及药物滥用，同时还能正常化脂质代谢。
• C2-substituted idan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20030130345A1

  公开（公告）日：2003-07-10

  Embodiments of the invention relate to C2-substituted indan-1-ones and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of embodiments of the invention include compounds of formula I 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for use as anorectics.

  该发明的实施例涉及C2-取代的茚烷酮及其生理上可接受的盐和生理功能衍生物。该发明的实施例化合物包括式I1的化合物，其中基团如所定义，并其生理上可接受的盐以及其制备方法。这些化合物例如适用于作为厌食药使用。
• Use of C2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity
  申请人：——

  公开号：US20030134882A1

  公开（公告）日：2003-07-17

  Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-one systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in methods of embodiments of the invention may include compounds of the formula 1 in which the radicals are as defined, and their physiologically acceptable salts.

  本发明实施例涉及减轻哺乳动物体重的方法，以及用于预防或治疗肥胖的方法，包括给予C2-取代的茚-1-酮体系及其生理上可接受的盐和生理功能衍生物。用于本发明实施例方法的化合物可能包括式1的化合物，其中基团如定义所示，以及它们的生理上可接受的盐。